For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Kura Oncology Inc (NASDAQ: KURA) closed at $7.9 down -2.11% from its previous closing price of $8.07. In other words, the price has decreased by -$2.11 from its previous closing price. On the day, 1.67 million shares were traded. KURA stock price reached its highest trading level at $8.15 during the session, while it also had its lowest trading level at $7.65.
Ratios:
For a deeper understanding of Kura Oncology Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.58. For the most recent quarter (mrq), Quick Ratio is recorded 6.16 and its Current Ratio is at 6.16. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27. Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 12 ’25 when WILSON TROY EDWARD bought 36,506 shares for $5.85 per share. The transaction valued at 213,578 led to the insider holds 37,474 shares of the business.
WILSON TROY EDWARD bought 13,494 shares of KURA for $89,623 on Aug 13 ’25. The President and CEO now owns 50,968 shares after completing the transaction at $6.64 per share. On May 19 ’25, another insider, Bair Teresa Brophy, who serves as the Chief Legal Officer of the company, sold 1,559 shares for $5.96 each. As a result, the insider received 9,292 and left with 107,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 685697920 and an Enterprise Value of 74442760. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.23 while its Price-to-Book (P/B) ratio in mrq is 2.24. Its current Enterprise Value per Revenue stands at 0.894 whereas that against EBITDA is -0.34.
Stock Price History:
The Beta on a monthly basis for KURA is 0.21, which has changed by -0.6091044 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $21.57, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 22.86%, while the 200-Day Moving Average is calculated to be 3.15%.
Shares Statistics:
For the past three months, KURA has traded an average of 1.51M shares per day and 1974350 over the past ten days. A total of 86.80M shares are outstanding, with a floating share count of 84.16M. Insiders hold about 3.04% of the company’s shares, while institutions hold 93.64% stake in the company. Shares short for KURA as of 1755216000 were 7996034 with a Short Ratio of 5.29, compared to 1752537600 on 8406094. Therefore, it implies a Short% of Shares Outstanding of 7996034 and a Short% of Float of 9.229999999999999.
Earnings Estimates
Investors are keenly observing as 8.0 analysts analyze and rate the current performance of Kura Oncology Inc (KURA) in the stock market.The consensus estimate for the next quarter is -$0.21, with high estimates of $0.65 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$0.4 and -$3.39 for the fiscal current year, implying an average EPS of -$2.24. EPS for the following year is -$2.2, with 8.0 analysts recommending between -$0.37 and -$4.93.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $453.9M, while the lowest revenue estimate was $29.4M, resulting in an average revenue estimate of $149.95M. In the same quarter a year ago, actual revenue was $53.88MBased on 13 analysts’ estimates, the company’s revenue will be $206.56M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
